Loading the session
Loading the session
Loading instrument
$15.56
+8.66%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 05:51 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +15.3% (SPY −1.6%, XLV +13.5%). 3 months: −23.2% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KARD, SPY and XLV · as of 4 Nov 2026
5.3M shares were sold short at the 15 Oct 2026 settlement; covering them would take 7.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $15.56 was 2.5% below its 50-day average ($15.96).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
October 6, 2026
−11.48%September 23, 2026
−11.68%September 2, 2026
+11.84%